Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer

摘要: Objectives. To conduct a preliminary investigation on statin use and its impact clinical presentation biochemical progression-free survival after brachytherapy. Methods. A total of 512 consecutive patients were treated with permanent brachytherapy for Stage T1c-T3aNxM0 prostate cancer at least 3 years before analysis. Biochemical was defined by prostate-specific antigen (PSA) level 0.4 ng/mL or less nadir. The median follow-up 5.3 years. clinical, treatment, dosimetric parameters evaluated included any specific statins, age, body mass index, PSA level, Gleason score, percentage positive biopsies, perineural invasion, volume, planning quality, supplemental external beam radiotherapy, tobacco use, hypertension, diabetes. Results. actuarial 8-year rate the entire group 94.6%. On forward conditional Cox regression analysis, pretreatment biopsies statistically significant predictors outcome. However, significantly lower biopsy cores, density earlier stage found in group. Almost every parameter comparison favored users. When stratified 97.0% taking statins compared 94.3% not 97.8% atorvastatin 94.7% other free progression. Conclusions. results this longest reported period to date suggest that especially atorvastatin, may improve most presentations nonsignificant improvement survival. UROLOGY 66: 1150‐1154, 2005. © 2005 Elsevier Inc.